Inactivation of NF-κB

  • Fazlul H. Sarkar
  • Yiwei Li
Part of the M. D. Anderson Solid Tumor Oncology Series book series (MDA)

Pancreatic cancer is the fourth leading cause of cancer-related deaths among adults in the United States, with an estimated 37,170 new cases and 33,370 deaths in 2007 (1). Only 5% of all patients with pancreatic cancer survive 5 years after diagnosis (1). Even for those patients diagnosed with local disease, the 5-year survival rate is only 20%. The presence of occult or clinical metastases at the time of diagnosis together with the lack of effective chemotherapies contributes to the high mortality in patients with pancreatic cancer. Cancer cells’ resistance to chemotherapeutic agents is also a major cause of treatment failure in most solid tumors, especially for pancreatic cancer. The major culprits involved in the drug resistance include multidrug resistance gene (MDR), NF-κB, and Akt. Among them, NF-κB is an important molecule and is considered to be the master switch that promotes cell survival and protects cells from apoptotic cell death (2, 3).


Pancreatic Cancer Pancreatic Cancer Cell Human Pancreatic Cancer Pancreatic Cancer Cell Line Human Pancreatic Cancer Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Siegel R, Ward E, 2007, Cancer statistics, 2007. CA Cancer J Clin 57:43–66.PubMedGoogle Scholar
  2. 2.
    Wang CY, Mayo MW, Korneluk RG, 1998, NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683.PubMedGoogle Scholar
  3. 3.
    Karin M, 2006, Nuclear factor-kappaB in cancer development and progression. Nature 441:431–436.PubMedGoogle Scholar
  4. 4.
    Karin M, 2006, NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45:355–361.PubMedGoogle Scholar
  5. 5.
    Haefner B, 2002, NF-kappaB: arresting a major culprit in cancer. Drug Discov Today 7:653–663.PubMedGoogle Scholar
  6. 6.
    Orlowski RZ, Baldwin AS, 2002, NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8:385–389.PubMedGoogle Scholar
  7. 7.
    Ghosh G, Duyne G, van Ghosh S, 1995, Structure of NF-kappa B p50 homodimer bound to a kappa B site. Nature 373:303–310.PubMedGoogle Scholar
  8. 8.
    Karin M, Greten FR, 2005, NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759.PubMedGoogle Scholar
  9. 9.
    Wu M, Lee H, Bellas RE, 1996, Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J 15:4682–4690.PubMedGoogle Scholar
  10. 10.
    Antwerp DJ, Van Martin SJ, Kafri T, 1996, Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274:787–789.PubMedGoogle Scholar
  11. 11.
    Li L, Aggarwal BB, Shishodia S, 2004, Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101:2351–2362.PubMedGoogle Scholar
  12. 12.
    Liptay S, Weber CK, Ludwig L, 2003, Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. I nt J Cancer 105:735–746.Google Scholar
  13. 13.
    Wang W, Abbruzzese JL, Evans DB, 1999, The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5:119–127.PubMedGoogle Scholar
  14. 14.
    Fujioka S, Sclabas GM, Schmidt C, 2003, Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 9:346–354.PubMedGoogle Scholar
  15. 15.
    Fujioka S, Sclabas GM, Schmidt C, 2003, Inhibition of constitutive NF-kappa B activity by I kappa B alpha Μ suppresses tumorigenesis. Oncogene 22:1365–1370.PubMedGoogle Scholar
  16. 16.
    Wang W, Abbruzzese JL, Evans DB, 1999, Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 18:4554–4563.PubMedGoogle Scholar
  17. 17.
    Banerjee S, Zhang Y, Ali S, 2005, Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65:9064–9072.PubMedGoogle Scholar
  18. 18.
    Fahy BN, Schlieman MG, Virudachalam S, 2004, Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198:591–599.PubMedGoogle Scholar
  19. 19.
    Li Y, Ahmed F, Ali S, 2005, Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65:6934–6942.PubMedGoogle Scholar
  20. 20.
    Chuang SE, Yeh PY, Lu YS, 2002, Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 63:1709–1716.PubMedGoogle Scholar
  21. 21.
    Arlt A, Vorndamm J, Muerkoster S, 2002, Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62:910–916.PubMedGoogle Scholar
  22. 22.
    Muerkoster S, Arlt A, Sipos B, 2005, Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 65:1316–1324.PubMedGoogle Scholar
  23. 23.
    Li Y, Sarkar FH, 2002, Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8:2369–2377.PubMedGoogle Scholar
  24. 24.
    Zhang Y, Banerjee S, Wang Z, 2006, Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. Cancer Res 66:1025–1032.PubMedGoogle Scholar
  25. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of Intraepithelial neoplasia and cancer—a plan to move forward. Clin Cancer Res 2006, 1078–1432.Google Scholar
  26. 26.
    Sarkar FH, Li Y, 2006, Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66:3347–3350.PubMedGoogle Scholar
  27. 27.
    Aggarwal BB, Shishodia S. 2006, Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421.PubMedGoogle Scholar
  28. 28.
    Surh YJ. 2003, Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768–780.PubMedGoogle Scholar
  29. 29.
    Davis JN, Kucuk O, Sarkar FH, 1999, Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 35:167–174.PubMedGoogle Scholar
  30. 30.
    Davis JN, Kucuk O, Djuric Z, 2001, Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 30: 1293–1302.PubMedGoogle Scholar
  31. 31.
    Li Y, Ellis KL, Ali S, 2001, Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 28:e90–e95.Google Scholar
  32. 32.
    Hwang JT, Ha J, Park OJ, 2005, Combination of 5-fluorouracil and genistein induces apopto-sis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 332: 433–440.PubMedGoogle Scholar
  33. 33. Satoh H, Nishikawa K, Suzuki K, 2003, Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. Res Commun Mol Pathol Pharmacol 113-114:149-158.Google Scholar
  34. 34.
    Tanos V, Brzezinski A, Drize O, 2002, Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol 102:188–194.PubMedGoogle Scholar
  35. 35.
    Takimoto CH, Glover K, Huang X, 2003, Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 12:1213–1221.PubMedGoogle Scholar
  36. 36.
    Miquel J, Bernd A, Sempere JM, 2002, The curcuma antioxidants: pharmacological effects and prospects for future clinical use. Arch Gerontol Geriatr 34:37–46 A review.PubMedGoogle Scholar
  37. 37.
    Banerjee M, Tripathi LM, Srivastava VM, 2003, Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 25:213–224.PubMedGoogle Scholar
  38. 38.
    Rao CV, Rivenson A, Simi B, 1995, Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55:259–266.PubMedGoogle Scholar
  39. 39.
    Bharti AC, Donato N, Singh S, 2003, Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053–1062.PubMedGoogle Scholar
  40. 40.
    Duvoix A, Morceau F, Delhalle S, 2003, I nduction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochem Pharmacol 66:1475–1483.PubMedGoogle Scholar
  41. 41.
    Chuang SE, Yeh PY, Lu YS, 2002, Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexame-thasone, and curcumin in carcinoma cells. Biochem Pharmacol 63:1709–1716.PubMedGoogle Scholar
  42. 42.
    Aggarwal BB, Shishodia S, Takada Y, 2005, Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11:7490–7498.PubMedGoogle Scholar
  43. 43.
    Lev-Ari S, Zinger H, Kazanov D, 2005, Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 59(Suppl 2):S276–S280.PubMedGoogle Scholar
  44. 44.
    Kunnumakkara AB, Guha S, Krishnan S, 2007, Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853–3861.PubMedGoogle Scholar
  45. 45.
    Notarbartolo M, Poma P, Perri D, 2005, Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible rela-tionship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 224:53–65.PubMedGoogle Scholar
  46. 46.
    Bava SV, Puliappadamba VT, Deepti A, 2005, Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280:6301–6308.PubMedGoogle Scholar
  47. 47.
    Venkatraman M, Anto RJ, Nair A, 2005, Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 44:51–59.PubMedGoogle Scholar
  48. 48.
    Sharma RA, Euden SA, Platton SL, 2004, Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847–6854.PubMedGoogle Scholar
  49. 49.
    Cheng AL, Hsu CH, Lin JK, 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895–2900.PubMedGoogle Scholar
  50. 50.
    Nho CW, Jeffery E, 2004, Crambene, a bioactive nitrile derived from glucosinolate hydrolysis, acts via the antioxidant response element to upregulate quinone reductase alone or synergisti-cally with indole-3-carbinol. Toxicol Appl Pharmacol 198:40–48.PubMedGoogle Scholar
  51. 51.
    Benabadji SH, Wen R, Zheng JB, 2004, Anticarcinogenic and antioxidant activity of diin-dolylmethane derivatives. Acta Pharmacol Sin 25:666–671.PubMedGoogle Scholar
  52. 52.
    Aggarwal BB, Ichikawa H. 2005, Molecular targets and anticancer potential of indole-3-car-binol and its derivatives. Cell Cycle 4:1201–1215.PubMedGoogle Scholar
  53. 53.
    Firestone GL, Bjeldanes LF, 2003, Indole-3-carbinol and 3-3Î-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 133: 2448S–2455S.PubMedGoogle Scholar
  54. 54.
    Li Y, Chinni SR, Sarkar FH, 2005, Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 10:236–243.PubMedGoogle Scholar
  55. 55.
    Rahman KW, Sarkar FH, 2005, Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 65:364–371.PubMedGoogle Scholar
  56. 56.
    Cover CM, Hsieh SJ, Cram EJ, 1999, Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59:1244–1251.PubMedGoogle Scholar
  57. 57.
    Sarkar FH, Li Y. 2004, Indole-3-carbinol and prostate cancer. J Nutr 134: 3493S–3498S.PubMedGoogle Scholar
  58. 58.
    Naik R, Nixon S, Lopes A, 2006, A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. I nt J Gynecol Cancer 16:786–790.Google Scholar
  59. 59.
    Reed GA, Peterson KS, Smith HJ, 2005, A phase I study of indole-3-carbinol in women: toler-ability and effects. Cancer Epidemiol Biomarkers Prev 14:1953–1960.PubMedGoogle Scholar
  60. 60.
    Mukhtar H, Ahmad N, 1999, Green tea in chemoprevention of cancer. Toxicol Sci 52: 111–117.PubMedGoogle Scholar
  61. 61.
    Afaq F, Adhami VM, Ahmad N. 2003, Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate. Oncogene 22: 1035–1044.PubMedGoogle Scholar
  62. 62.
    Ahmad N, Gupta S, Mukhtar H. 2000, Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 376: 338–346.PubMedGoogle Scholar
  63. 63.
    Chen PC, Wheeler DS, Malhotra V, 2002, A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IkappaB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 26:233–241.PubMedGoogle Scholar
  64. 64.
    Yang F, Oz HS, Barve S, 2001, The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 60:528–533.PubMedGoogle Scholar
  65. 65.
    Takada M, Nakamura Y, Koizumi T, 2002, Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. Pancreas 25:45–48.PubMedGoogle Scholar
  66. 66.
    Lyn-Cook BD, Rogers T, Yan Y, 1999, Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutr Cancer 35:80–86.PubMedGoogle Scholar
  67. 67.
    Zhang Q, Wei D, Liu J, 2004, In vivo reversal of doxorubicin resistance by (-)-epigallocate-chin gallate in a solid human carcinoma xenograft. Cancer Lett 208:179–186.PubMedGoogle Scholar
  68. 68.
    Fremont L. 2000, Biological effects of resveratrol. Life Sci 66:663–673.PubMedGoogle Scholar
  69. 69.
    Shanafelt TD, Lee YK, Call TG, 2006, Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30:707–712.PubMedGoogle Scholar
  70. 70.
    Olas B, Wachowicz B, Saluk-Juszczak J, 2002, Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res 107:141–145.PubMedGoogle Scholar
  71. 71.
    Scarlatti F, Sala G, Somenzi G, 2003, Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 17:2339–2341.PubMedGoogle Scholar
  72. 72.
    Delmas D, Rebe C, Lacour S, 2003, Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 278:41482–41490.PubMedGoogle Scholar
  73. 73.
    Ding XZ, Adrian TE. 2002, Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25:e71–e76.PubMedGoogle Scholar
  74. 74.
    Estrov Z, Shishodia S, Faderl S, 2003, Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102: 987–995.PubMedGoogle Scholar
  75. 75.
    Kotha A, Sekharam M, Cilenti L, 2006, Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5:621–629.PubMedGoogle Scholar
  76. 76.
    Fulda S, Debatin KM, 2004, Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64:337–346.PubMedGoogle Scholar
  77. 77.
    Nkondjock A, Ghadirian P, Johnson KC, 2005, Dietary intake of lycopene is associated with reduced pancreatic cancer risk. J Nutr 135:592–597.PubMedGoogle Scholar
  78. 78.
    Kucuk O, Sarkar FH, Djuric Z, 2002, Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 227:881–885.Google Scholar
  79. 79.
    Calfee-Mason KG, Spear BT, Glauert HP, 2002, Vitamin E inhibits hepatic NF-kappaB activation in rats administered the hepatic tumor promoter, phenobarbital. J Nutr 132: 3178–3185.PubMedGoogle Scholar
  80. 80.
    Carcamo JM, Pedraza A, Borquez-Ojeda O, 2002, Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry 41:12995–13002.PubMedGoogle Scholar
  81. 81.
    Ohsugi T, Kumasaka T, Ishida A, 2006, I n vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. Leuk Res 30:90–97.PubMedGoogle Scholar
  82. 82.
    Watanabe M, Ohsugi T, Shoda M, 2005, Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106:2462–2471.PubMedGoogle Scholar
  83. 83.
    Poma P, Notarbartolo M, Labbozzetta M, 2006, Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol 28:923–930.PubMedGoogle Scholar
  84. 85.
    Sclabas GM, Uwagawa T, Schmidt C, 2005, Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 103:2485–2490.PubMedGoogle Scholar
  85. 86.
    Wong BC, Jiang X, Fan XM, 2003, Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 22:1189–1197.PubMedGoogle Scholar
  86. 87.
    Ali S, El-Rayes BF, Sarkar FH, 2005, Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 4:1943–1951.PubMedGoogle Scholar
  87. 88.
    El-Rayes BF, Ali S, Sarkar FH, 2004, Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 3:1421–1426.PubMedGoogle Scholar
  88. 89.
    Narayanan BA, Narayanan NK, Pttman B, 2006, Adenocarcinoma of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 66:257–265.PubMedGoogle Scholar
  89. 90.
    Han C, Wu T, 2005, Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280:24053–24063.PubMedGoogle Scholar
  90. 91.
    El-Rayes BF, Zalupski MM, Shields AF, 2005, A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs 23:583–590.PubMedGoogle Scholar
  91. 92.
    Zhang S, Lin ZN, Yang CF, 2004, Suppressed NF-kappaB and sustained JNK activation con-tribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis 25:2191–2199.PubMedGoogle Scholar
  92. 93.
    Yip-Schneider MT, Nakshatri H, Sweeney CJ, 2005, Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic car-cinoma cells. Mol Cancer Ther 4:587–594.PubMedGoogle Scholar
  93. 94.
    Muerkoster S, Arlt A, Witt M, 2003, Usage of the NF-kappaB inhibitor sulfasalazine as sensi-tizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 104:469–476.PubMedGoogle Scholar
  94. 95.
    Dong QG, Sclabas GM, Fujioka S, 2002, The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21: 6510–6519.PubMedGoogle Scholar
  95. 96.
    Lu Y, Wahl LM. 2005, Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol 78:259–265.PubMedGoogle Scholar
  96. 97.
    Meli M, D’Alessandro N, Tolomeo M, 2003, NF-kappaB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines. Ann N Y Acad Sci 1010:232–236.PubMedGoogle Scholar
  97. 98.
    Munshi A, Kurland JF, Nishikawa T, 2004, Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol Cancer Ther 3:985–992.PubMedGoogle Scholar
  98. 99.
    Garcia MG, Alaniz L, Lopes EC, 2005, Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 29:1425–1434.PubMedGoogle Scholar
  99. 100.
    Kim K, Ryu K, Ko Y, 2005, Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Haematol 131:59–66.PubMedGoogle Scholar
  100. 101.
    Pham LV, Tamayo AT, Yoshimura LC, 2003, Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171:88–95.PubMedGoogle Scholar
  101. 102.
    Hansson A, Marin YE, Suh J, 2005, Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor. Int J Oncol 27:941–948.PubMedGoogle Scholar
  102. 103.
    Tanaka A, Muto S, Konno M, 2006, A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res 66: 419–426.PubMedGoogle Scholar
  103. 104.
    Takada Y, Gillenwater A, Ichikawa H, 2006, Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281:5612–5622.PubMedGoogle Scholar
  104. 105.
    Imre G, Gekeler V, Leja A, 2006, Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 66:5409–5418.PubMedGoogle Scholar
  105. 106.
    Gao N, Dai Y, Rahmani M, 2004, Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 66:956–963.PubMedGoogle Scholar
  106. 107.
    Rundall BK, Denlinger CE, Jones DR. 2004, Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136:416–425.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Fazlul H. Sarkar
    • 1
  • Yiwei Li
    • 1
  1. 1.Karmanos Cancer InstituteWayne State University School of MedicineDetroitUSA

Personalised recommendations